Urinary polyphenols and breast cancer risk: results from the Shanghai Women¡¯s Health Study
详细信息 查看全文
- 作者：Jianfeng Luo ; Yu-Tang Gao ; Wong-Ho Chow ; Xiao-Ou Shu ; Honglan Li ; Gong Yang ; Qiuyin Cai ; Nathaniel Rothman ; Hui Cai and Martha J. Shrubsole ; et al.
- 关键词：Breast cancer ; Urinary polyphenols ; Flavanols ; Flavonols
- 刊名：Breast Cancer Research and Treatment
- 出版年：2010
- 出版时间：April, 2010
- 年：2010
- 卷：120
- 期：3
- 页码：693-702
- 全文大小：249.5 KB
文摘
Polyphenols, the most abundant dietary antioxidants, also possess many other anticarcinogenic activities. Urinary metabolites of polyphenols could complement dietary assessment of the bioavailability of these nutrients. We conducted a study of 353 incident breast cancer cases and 701 individually matched controls nested within the Shanghai Women’s Health Study cohort of women aged 40–70 years at baseline. Liquid chromatography photo-diode array electrospray mass spectrometry was used to measure tea polyphenols (epicatechin, epigallocatechin, and their metabolites) and flavonols (e.g., quercetin and kaempferol). Multivariate conditional logistic regression analyses were used to assess associations between breast cancer risk and urinary excretion rates of polyphenols. Urinary excretion of tea polyphenols increased with increasing tea leaves consumed among controls, but not among breast cancer cases. Compared with cases, controls had higher levels of urinary total polyphenols and tea polyphenols, particularly epicatechin. In contrast, we did not find any dose–response relationship between urinary polyphenols and breast cancer risk. Urinary excretion of epicatechin was inversely associated with breast cancer risk [odds ratio (OR) and 95 % confidence interval (CI) of 0.59 (0.39–0.88) for the intermediate tertile]. In spline regression, we found an overall dose–response relationship between epicatechin level and risk of breast cancer, although it was not apparent in low and middle urinary excretion range. In conclusion, high epicatechin may be related to a reduced risk of breast cancer. Further studies are warranted to confirm our findings.